Actions

Mylan may have overcharged taxpayers $1.27 billion for EpiPen

Mark Zaleski

<p>This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Mylan reports financial results Tuesday, Aug. 9, 2016. (AP Photo/Mark Zaleski, File)</p>

Taxpayersmay have paid extra $1.27B for EpiPen

By: WMAR Staff

Posted at 8:54 AM, Jun 01, 2017

and last updated 2017-06-01 08:54:25-04

The pharmaceutical company behind the life-saving EpiPen allergy injection may have overcharged the federal government by more than $1 billion.

The Department of Health and Human Services wrote a letter to Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, to inform the committee that Mylan may have swindled $1.27 billion from taxpayers over the past 10 years.

Mylan is accused of incorrectly classifying the EpiPen as a generic drug instead of a brand name. This allowed the company to provide Medicaid less in rebates. Taxpayers ended up with a bigger bill.

Mylan is in the process of finalizing a $465 million settlement with the Department of Justice over the misclassification.

About WMAR

An in depth look at getting back to work and making ends meet.

4:51 PM, May 16, 2019

Actions

Mylan may have overcharged taxpayers $1.27 billion for EpiPen

Sign up for the Headlines Newsletter and receive up to date information.

now signed up to receive the Headlines Newsletter.

An in depth look at getting back to work and making ends meet.